Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Aileron Therapeutics, Inc. ALRN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
37/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Aileron Therapeutics, Inc. (ALRN) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 4 Buy, 1 Hold.

ALRN Analyst Ratings

Buy
5
Ratings
4 Buy
1 Hold
Based on 5 analysts giving stock ratings to Aileron Therapeutics, Inc. in the past 3 months
Rating breakdown
Buy
4 80%
Hold
1 20%
80%
Buy
4 analysts
20%
Hold
1 analysts
0%
Sell
0 analysts

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 CBIO
CBIO
Catalyst Biosciences, Inc.
$19.52
+8.50%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 BNTC
BNTC
Benitec Biopharma Inc.
$13.25
+10.42%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 MGTA
MGTA
Magenta Therapeutics, Inc.
$0.70
-7.74%
 SABS
SABS
SAB Biotherapeutics, Inc.
$3.86
-1.03%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message